Biogen Inc.: Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis (tocilizumab)
Biosimilars have the potential to enable greater access to marketed biologic therapies while generating cost savings and healthcare sustainability
CAMBRIDGE, Mass. and GUANGZHOU, China, April 08, 2021Inc. (Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. (688177.SH) today announced that they entered into a commercialization and license agreement to develop, manufacture and commercialize BAT1806, a Phase 3 clinical stage anti-interleukin-6 (IL-6) receptor monoclonal antibody that is a proposed biosimilar referencing ACTEMRA
1 (tocilizumab).
ACTEMRA s primary indication is for moderate to severe rheumatoid arthritis in adults as well as juvenile idiopathic polyarthritis, systemic juvenile idiopathic arthritis, giant cell arteritis and cytokine release syndrome. In 20
Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Message :
Required fields
TYSABRI is a well-established high-efficacy treatment that now provides two routes of administration enabling flexibility to meet patients individual preferences and needs
The subcutaneous option provides a shorter administration time and expands access to treatment for patients and physicians beyond the infusion setting
The approval adds to Biogen’s strong MS portfolio and is part of its leading, innovative work to improve the understanding of optimal clinical outcomes as part of the long-term treatment of patients with MS
CAMBRIDGE, Mass., April 07, 2021 (GLOBE NEWSWIRE) Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission (EC) has granted marketing authorization for a subcutaneous (SC) injection of TYSABRI® (natalizumab) to treat relapsing-remitting multiple sclerosis (MS). The new route of administration offers comparable efficacy and safety to the TYSABRI intravenous (IV) formulation building on the therapy’s long-term
(0)
TYSABRI is a well-established high-efficacy treatment that now provides two routes of administration enabling flexibility to meet patients individual preferences and needs
The subcutaneous option provides a shorter administration time and expands access to treatment for patients and physicians beyond the infusion setting
The approval adds to Biogen s strong MS portfolio and is part of its leading, innovative work to improve the understanding of optimal clinical outcomes as part of the long-term treatment of patients with MS
CAMBRIDGE, Mass., April 07, 2021(Nasdaq: BIIB) today announced that the European Commission (EC) has granted marketing authorization for a subcutaneous (SC) injection of TYSABRI (natalizumab) to treat relapsing-remitting multiple sclerosis (MS). The new route of administration offers comparable efficacy and safety to the TYSABRI intravenous (IV) formulation building on the therapy s long-term data, established clinical benefits and well-characterized saf
The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat Relapsing-Remitting Multiple Sclerosis forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.